CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.20751427

Available online at: http://www.iajps.com Review Article

EVOLVING TRENDS IN UROPATHOGEN RESISTANCE: A COMPREHENSIVE REVIEW OF GLOBAL ANTIBIOGRAM PATTERNS AND STEWARDSHIP IMPLICATIONS.

Rincy.K.Geevarghese[1], Fathimathsafa[1], Mrs.Vineetha.S[2], Dr.T.Tamilselvan[3]
[1]4 th Semester ,M.Pharm Students,Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588.
[2]Associate Professor, Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588.
[3]HOD & Professor,Department of Pharmacy Practice, Nehru College of Pharmacy, Thiruvilwamala, Thrissur,680588.

Abstract:

A significant global threat to public health and clinical management of urinary tract infections (UTIs) is posed by the increasing prevalence of antimicrobial resistance (AMR) in uropathogens [3,11]. This review provides a synthesis of the findings from the recent research studies that were carried out in a variety of geographical regions to evaluate the distribution of common pathogens and the evolving antibiotic susceptibility patterns of these pathogens [1-2,4-10]. Before culture results are available, an antibiogram helps clinicians choose the best antibiotics by providing cumulative data on bacterial susceptibility within a healthcare facility. Additionally, by encouraging sensible antibiotic use and lowering needless exposure to broad-spectrum agents, antibiograms greatly support antimicrobial stewardship initiatives. The epidemiology, pathogenesis, microbiology, risk factors, antimicrobial resistance mechanisms, clinical implications, diagnostic techniques, and treatment approaches of UTIs are all covered in this narrative review[1,2].According to the available research, Escherichia coli is the most common type of bacteria isolated , followed by Klebsiella species [4,5]. Furthermore, there are concerning trends of resistance to commonly prescribed empiric antibiotics such as ciprofloxacin and amoxicillin-clavulanate [1,2,6,7]. The regional variations [8,9], socioeconomic disparities in healthcare [10], and the impact of the COVID-19 pandemic on prescribing habits [11] all contribute to the complexity of these resistance patterns. It is the purpose of this review to highlight the critical role that institutional cumulative antibiograms [12], the implementation of robust antimicrobial stewardship programs [13], and the adoption of rapid diagnostic technologies [14] play in bridging the gap between empirical treatment and clinical efficacy. Finally, in order to maximize patient outcomes and reduce the number of treatment failures, it is necessary to have evidence-based, locally administered therapy that is guided by ongoing surveillance and analysis.[1,11].

Keywords: *Antimicrobial resistance, Uropathogens, Antibiogram, Urinary tract infection, Antimicrobial stewardship,Multidisciplinary stewardship,Diagnostic stewardship.*

Corresponding author:
Rincy.K.Geevarghese,
4 th Semester ,M.Pharm Students,
Department of Pharmacy Practice,
Nehru College of Pharmacy,
Thiruvilwamala, Thrissur,680588.

QR CODE

Please cite this article in press Rincy.K.Geevarghese et al Evolving Trends In Uropathogen Resistance: A Comprehensive Review Of Global Antibiogram Patterns And Stewardship Implications, Indo Am. J. P. Sci, 2026; 13(06).

INTRODUCTION:

Urinary tract infections are among the most prevalent infectious diseases in both community and hospital settings. It can affect people of all ages and genders, though due to physiological and anatomical factors, women are far more vulnerable and can cause substantial morbidity and medical expenses.Urinary tract infections can affect the kidneys and ureters in the upper urinary tract or the bladder and urethra in the lower urinary tract. The infection can range in severity from simple cystitis to potentially fatal pyelonephritis and urosepsis. Antimicrobial resistance in uropathogens has become one of the biggest threats to successful treatment over the past few decades[1]. Despite the fact that there are well-established empirical treatment options , the widespread and frequently inappropriate use of antibiotics has hastened the evolution of resistance among common uropathogens [1,11]. The fact that resistance patterns change over time within the same institution [1,11,15,16] as well as by region [1,8,9] adds to the clinical challenge. A consequence of this is that relying on guidelines that are either out of date or generic frequently results in inappropriate empiric therapy and poor outcomes for patients [1,11,15]. In order to improve clinical decision-making, this review examines the current global landscape of uropathogen resistance, analyzing the factors that contribute to these patterns and investigating evidence-based strategies like the use of cumulative antibiograms and stewardship initiatives.Understanding the function of institutional antibiograms is essential for doctors to transition from antiquated empirical techniques towards more accurate,evidence-based care of urinary tract infections,given the increasing prevalence of multidrug-resistant organisms and the heterogeneity of local resistance patterns.[1,11,12]

CLASSIFICATION OF URINARY TRACT INFECTIONS

Clinical presentation, host characteristics (such as the existence of anatomical or functional abnormalities), and disease severity are typically used to categorize urinary tract infections (UTIs). The main differentiation is between complicated and uncomplicated infections, a categorization system that directs empirical antibiotic therapy and evaluates risk.[42,43,44]

Table 1.Classification of Urinary Tract Infections

Category	Clinical definition	Common characteristics
Uncomplicated UTI	Infection in a healthy individual without structural or functional abnormalities of urinary tract infections	Primarily affects premenopausal, non-pregnant women; include acute cystitis and pyelonephritis.
Complicated UTI	Infection associated with conditions that increase the risk of therapy failure or disease progression	Associated with urinary tract abnormalities (obstruction stones), catheterization, diabetes, Pregnancy or immunocompromised states.
Recurrent UTI	Frequent episodes of infection occurring after the resolution of a previous confirmed UTI	Defined as> 2 infections in 6 months or > 3 in 12 months.
Asymptomatic bacteriuria	Significant bacterial growth in urine without associated clinical symptoms	Often does not require treatment except in specific populations (eg; pregnancy or pre-urologic surgery)

LITERATURE SEARCH STRATEGY

Major biomedical databases, such as PubMed/MEDLINE and Google Scholar, were thoroughly searched for recent, relevant peer-reviewed publications that had recently been published. Words and phrases like "uropathogens," "antimicrobial resistance," "antibiogram," "urinary tract infections," and "susceptibility patterns" were employed. Included were studies that evaluated the resistance profiles and distribution of causative organisms in community or tertiary care settings. Forty – four core studies, including retrospective analyses and cross-sectional studies, were included in the final selection . These studies captured a range of patient demographics and geographical locations, offering a global synthesis of data [1-44].

ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) is the result of microorganisms, such as bacteria, viruses, fungi, and parasites, evolving over time to withstand exposure to medications intended to eradicate them [33]. This adaptation makes conventional medical treatments ineffective, which makes it possible for infections to linger, get worse, and spread quickly to other people [34, 35]. Antimicrobial resistance has a serious worldwide impact. Over the next few decades, bacterial Antimicrobial resistance is predicted to cause tens of millions of deaths, with low- and middle-income areas most at risk [36].

MECHANISM OF ANTIMICROBIAL RESISTANCE

a)Enzymatic Inactivation**:** Before a drug can be harmful, microbes can produce specialized enzymes that chemically break down or neutralize its structure [36, 37]. The production of beta-lactamase enzymes by bacteria to break down the central chemical ring of cephalosporins and penicillins are a well-known example [37].

b)Active Efflux Pumps: Efflux pumps are tiny protein channels found in the cell membranes of many resistant bacteria [36,37]. In order to keep the drug from ever reaching a deadly concentration, these pumps actively vacuum up incoming antibiotics and expel them from the cell [36, 37].

c)Target Site Modification: To interfere with a pathogen's cellular machinery, antimicrobial medications bind to particular molecular targets within the pathogen [36]. Microbes can subtly change the structural shape of these target sites through genetic mutation [36, 37]. While the internal components of the microbes continue to function normally, the drug can no longer attach correctly, making it useless [36].

d)Decreased Membrane Permeability: Pathogens can selectively block protein channels (porins) or change the structure of their outer cell walls [36, 37]. Antimicrobial molecules are unable to physically enter the cell's outer boundaries due to this structural bottleneck [36].

The major factors for antimicrobial resistance includes

a)Misuse and Overuse in Human Medicine: The improper prescription of antimicrobial medications is a significant contributor to resistance [33]. When standard antibacterial antibiotics are prescribed for viral illnesses like the common cold or influenza, for example, the virus is not cured; instead, healthy bacteria are needlessly destroyed and surviving strains are under tremendous pressure to adapt [33, 34]

b)Agricultural and Livestock Practices: Entire populations of healthy animals are given critically important human antimicrobials in many industrial farming and aquaculture sectors worldwide [1]. Massive environmental reservoirs of highly resistant genes are created by these drugs, which are frequently used as inexpensive growth promoters or preventative disease preventatives rather than to treat active illness [33, 35]

c)Incomplete Treatment Regimens: The drug concentration falls too low to completely eradicate the infection if the recommended duration or dosage of an antimicrobial treatment is not followed [34]. A resilient, partially exposed subpopulation that is capable of surviving, mutating, and proliferating is left behind after the most vulnerable microbes perish first [34, 37]

d)Environmental and Sanitary Deficiencies: Drug-resistant "superbugs" can spread swiftly through nearby communities and waterways due to inadequate infection control procedures in overcrowded healthcare facilities, as well as a lack of access to clean water and dependable sanitation infrastructure . [33, 35]

ANTIMICROBIAL STEWARDSHIP

Antimicrobial Stewardship (AMS) is a coordinated set of interventions intended to enhance and measure the appropriate use of antimicrobial agents by encouraging the choice of the best antimicrobial drug regimen, dose, length of therapy, and mode of administration. It is a systematic, organizational approach implemented within healthcare networks to optimize the use of antimicrobial agents [33, 38]. Antimicrobial stewardship’s main goal is to minimize toxicity and adverse events while ensuring that a patient receives the best antibiotic at the right dose, through the best route, and for the exact amount of time required to cure an infection [38, 39]. More broadly, these initiatives protect the effectiveness of current drugs for coming generations by acting as the first line of defense against the worldwide threat of antimicrobial resistance (AMR) [33, 41].

CORE STRATEGIES OF ANTIMICROBIAL STEWARDSHIP

Restrictive and persuasive clinical interventions are key components of successful institutional AMS programs, and they are frequently overseen by a multidisciplinary team made up of microbiologists, clinical pharmacists, and infectious disease doctors [39, 41].

a)Prospective Audit and Feedback

This approach, which is frequently regarded as the foundation of active stewardship, entails an AMS team reviewing active antibiotic orders after a predetermined amount of time, usually 48 to 72 hours [38, 39]. Antibiogram profiles and preliminary microbiology culture results are typically available by this point [3]. The team gives the prescribing physician clear, immediate advice on how to either reduce the drug's spectrum (de-escalation), modify the dosage according to organ function, or stop treatment if an infection is ruled out [38, 41].

b) Formulary restriction and Pre-authorization

In order for the pharmacy to dispense a high-priority, broad-spectrum antibiotic (like Meropenem or Linezolid), frontline clinicians must first receive formal approval from an infectious disease specialist or clinical pharmacist [39, 41]. By strictly limiting their use to confirmed multi-drug-resistant infections, this gatekeeping mechanism prevents the indiscriminate use of "last-line" agents [38, 41].

c) De-escalation of Therapy

Once microbiological culture and susceptibility results are obtained, empirical broad-spectrum antibiotics should be limited. De-escalation eliminates side effects, lessens selective pressure for resistant organisms, and limits needless exposure to broad-spectrum medicines.

d) Infection Prevention and Control Measures

To stop the spread of resistant organisms, antimicrobial stewardship collaborates closely with infection control initiatives by compliance with hand hygiene,precautions for isolation, cleaning of the environment, disinfection and sterilization, bundles for catheter care, preventing surgical site infections and immunization campaigns.[38]

DETERMINANTS AND BARRIERS TO ANTIMICROBIAL STEWARDSHIP

The efficacy of antibiotic therapy and surveillance is determined by a complex interplay of clinical, methodological, and systemic factors.

A) METHODOLOGICAL CHALLENGES IN SURVEILLANCE

The absence of standardized reporting is one of the main challenges to accurate resistance monitoring [12]. Real-time cumulative antibiogram generation is challenging in many hospitals due to the integration of microbiology laboratory data into clinical decision-support systems [12].

B) GEOGRAPHICAL AND CLINICAL DISPARITIES

Local prescription practices and patient populations have a major impact on resistance profiles [1,8,9,11]. Research shows that compared to community-based settings, tertiary care settings frequently report higher rates of multidrug-resistant (MDR) organisms, which calls for site-specific therapy rather than universal protocols [11,17].

Table no: 2 Barriers to Effective UTI Management

Category of Barrier	Contributing factors
Methodological	Inconsistent data collection[12],lack of automated reporting[12]
Clinical	High prevalence of MDR organisms[11,17],empiric therapy reliance[1]
Systemic	Limited resources for diagnostic testing[13,18],high drug cost[10]
Educational	Poor adherence to stewardship guidelines by prescribers[13]

INTEGRATION OF MODERN DIAGNOSTICS AND STEWARDSHIP

Clinical practices must shift to personalized and rapid-response models in order to combat growing resistance.

A) RAPID DIAGNOSTIC TECHNOLOGIES:

Even though they are widely used, traditional culture-based techniques are slow by nature, frequently taking up to 72–96 hours to produce conclusive identification and susceptibility results[28]..Instead of using laborious, conventional culture methods, modern diagnostics like metagenomic sequencing enable precise pathogen identification and susceptibility profiling in much shorter amounts of time [14]. Metagenomic next-generation sequencing (mNGS)is a transformative tool that enables a culture-independent approach which , can directly identify pathogens and resistance genes from clinical specimens.Technologies like multiplex PCR panels and mass spectroscopy provide rapid identification.This enables earlier de-escalation of antibiotics-switching from broad-spectrum to targeted therapy-which is the cornerstone of effective stewardship.[29][30]

B) MULTIDISCIPLINARY STEWARDSHIP:

Optimizing therapy requires integrated approaches involving clinicians, pharmacists, and microbiologists [13]. The best defense against treatment failure is shown by programs that prioritize rigorous adherence to locally derived antibiograms [1] and regular audits of antibiotic prescriptions [11].The effective management of complicated urinary tract infections requires applying site-specific resistance data to achieve PK/PD targets,ensuring that the selected empiric therapy is both safe and potent.[31]

a)Pharmacist Integration: In order to ensure adequate dosing based on pharmacokinetic/pharmacodynamics (PK/PD) targets,audit prescriptions and avoid drug-related toxicities,pharmacists are essential.Pharmacokinetic/pharmacodynamic factors are essential for optimizing antimicrobial dosing since they guarantee that medication concentrations stay above the minimum inhibitory concentrations(MIC).Pharmacists can modify antibiotic regimens by incorporating PK/PD targets into clinical practice,which is crucial for optimizing treatment efficacy and halting the emergence of new resistance.[31]

b)Microbiology's Strategic role**:**Clinical microbiologists provide cumulative antibiograms,which are crucial reports that provide an overview of regional resistance patterns.When a patient first arrives,before individual culture results are available,these reports are essential for directing empirical therapy.[5]

Diagnostic stewardship: The goal of diagnostic stewardship is to make sure that the appropriate test is ordered for the appropriate patient at the appropriate time.It decreases false positive results that result in needless antibiotic prescriptions by eliminating needless pan-cultures and reflexive testing.[32]

ROLE OF ANTIBIOGRAM IN CLINICAL PRACTICE

An antibiogram is an institutional periodic summary of clinical data that tabulates the cumulative susceptibility patterns of local bacterial isolates to a specific panel of antimicrobial drugs [33].Antibiograms are essential institutional tools that help clinicians make well informed decisions about empirical therapy by tracking local trends in antibiotic resistance.These reports help choose the best antimicrobial medicines by offering an organized summary of pathogen susceptibility,which lessens the need for broad-spectrum antibiotics.Antibiogram data integration into clinical workflows makes it easier to optimize medication regimens,guaranteeing that patients receive focused care that reduces toxicity and enhances therapeutic results.[1,2,3]

FUTURE PERSPECTIVES

In order to ensure data-driven responses to emerging diseases,future efforts should focus on the widespread adoption of digital systems such as WHONET for the real-time tracking of antibiotic resistance.To reduce antibiotic abuse and stop the development of resistant organisms,antimicrobial stewardship programs must be integrated into all levels of healthcare,including primary care,is essential to curb the misuse of antibiotics and limit the spread of resistant organisms.Rapid diagnostic technology adoption will be essential for identifying uropathogens more quickly,which will enable timely clinical treatments and lessen the need for broad-spectrum empirical therapy.In the end,switching from point-in-time investigations to ongoing longitudinal surveillance would enable more accurate and proactive treatment approaches by offering deeper insights into evolving resistance pattern of uropathogens.

CONCLUSION:

Achieving optimal outcomes for UTI patients necessitates more than standard empirical treatment [1]. Critical factors contributing to therapeutic failure include regional variations in resistance [1, 8, 9], the rise of ESBL-producing organisms [17], and the limitations of traditional diagnostic workflows [12, 14]. Increasing diagnostic precision through rapid technologies [14], standardizing cumulative antibiograms [1,12], and enforcing robust interdisciplinary antimicrobial stewardship are important [1,11,13]. To optimize long-term health, future clinical processes must consistently incorporate evidence-based strategies that bridge the gap between empirical prescription and true clinical efficacy.[Modern clinical microbiology urgently needs to implement a comprehensive,multifaceted approach to effectively overcome these intricate obstacles.Three essential pillars must be given priority in this progression first one is increasing diagnostic precision ie, inorder to give doctors correct information in shorter amount of time and enable quicker targeted intervention rather than protracted empirical therapy,rapid diagnostic technology integration is crucial[14].Second one is standardizing surveillance tools which ensure that empirical decisions are based on local,site-specific susceptibility profiles,institutional standardization of cumulative antibiograms is essential for converting unprocessed laboratory data into useful clinical knowledge[1,12].Lastone is enforcing interdisciplinary stewardship which guarantee the advancement in microbiology and diagnostics are effectively transferred into improved bedside practice,strong,interdisciplinary antimicrobial stewardship programs are required.[1,11,13].In the end,future therapeutic procedures must consistently and methodically integrate these evidence-based approaches in order to optimize long-term patient health and prevent the emergence of antibiotic resistance [14].Healthcare systems can guarantee that urinary tract infection treatment continues to be effective in a time of changing bacterial threats by bridging the ongoing gap between initial empirical prescription and genuine clinical efficacy[1,13].

REFERENCES:

1.Haindongo EH, Funtua B, Singu B, Hedimbi M, Kalemeera F, J. Antimicrobial resistance among bacteria isolated from urinary tract infections in females in Namibia, 2016–2017. *Journal of Research in Medical Sciences.* 2017 June;5(6):2718-2722. doi:10.18203/2320-6012.ijrms20171855.

2.Yadav M, Pal R, Damrolien S, Khumanthem SD. Microbial spectrum of urinary tract infections and its antibiogram in a tertiary care hospital. .

International Journal of Research in Medical Sciences. 2017 Jun;5(6):2718-2722. doi:10.18203/2320-6012.ijrms20172476.

3.Vakilzadeh MM, Heidari A, Mehri A, Shirazinia M, Sheybani F, Aryan E, et al. Antimicrobial Resistance among Community-Acquired Uropathogens in Mashhad, Iran. *Journal of Environmental and Public Health*.2020;2020:3439497.doi:10.1155/2020/3439497.

4.Mohamoud H, Tadesse S, Derbie A. Antimicrobial resistance and ESBL profile of Uropathogens among pregnant women at Edna Adan Hospital, Hargeisa, Somaliland.*Journal of Environmental and Public Health*.2020;2020:3439497.doi:10.1155/2020/3439497.

5.Moehring RW, Hazen KC, Hawkins MR, Drew RH, Sexton DJ, Anderson DJ. Challenges in Preparation of Cumulative Antibiogram Reports for Community Hospitals. *American Journal of Infection Control*. 2018 Jan;46(1):64-68. doi:10.1016/j.ajic.2017.07.017.

6.Dreser A, Hegewisch-Taylor J, Cortés-Ortiz MA, Levy-Hara G. Progress and challenges in the implementation of antimicrobial stewardship programs in 50 hospitals in Mexico. *Journal of Global Antimicrobial Resistance*.2025;43:40-50.doi:10.1016/j.jgar.2025.02.018

7.Bellankimath AB, Branders S, Kegel I, Ali J, Asadi F, Johansen TEB. Metagenomic sequencing enables accurate pathogen and antimicrobial susceptibility profiling in complicated UTIs in approximately four hours. Nature Communications. 2025;16:558. doi:10.1038/s41467-025-66865-8.

8.Hussain T, Moqadasi M, Malik S, Zahid AS, Nazary K, Shafi. Uropathogens Antimicrobial Sensitivity and Resistance Pattern From Outpatients in Balochistan, Pakistan. Cereus.2021 Aug 28;13(8):e 17527.doi:10.7759/cureus.17527

9.Mohamed AA, Bastug Y, Senol C, Kassim MM. Antimicrobial resistance pattern and uropathogens distribution in children visiting a referral hospital in Mogadishu. Future Sci OA.2024;10(1):FSO978.doi:10.2144/fsoa-2023-0298

10.Al-Zahrani J, Al Dossari K, Gabr AH, Ahmed AF, Al Shahrani SA, Al-Ghamdi S. Antimicrobial resistance patterns of Uropathogens isolated from adult women with acute uncomplicated cystitis. BMC Microbiology.2019;19(1):237.doi:10.1186/s12866-019-1612-6

11.Patil G, Patil D, Patil A, Shrikhande S. Microbiological Profile and Antimicrobial Susceptibility Pattern of Uropathogens Isolated From Pregnant Women Attending a Tertiary Care Hospital in Central India. Cureus. 2024 Oct 3;16(10):e70798. doi:10.7759/cureus.70798.

12.Kaur J, Bhat P, Bhumbla U. Fosfomycin susceptibility in multidrug resistant uropathogens: A retrospective study in the era of antimicrobial resistance .*Journal of Family Medicine and Primary Care*.2025;14(4):1346-1351.

13.Abdel Gawad AM, Ashry WMO, El-Ghannam S, Hussein M. Antibiotic resistance profile of common uropathogens during COVID-19 pandemic: hospital based epidemiologic study. BMC Microbiology.2023;23(1).doi:10.1186/s12866-023-02773-5.

14 Silva CE, Carvalho PHS, Capretz GCG, Ciriaco YS, Souza WHMS, Alves MEFS, et al. Profile of antimicrobial resistance of uropathogens in urinary tract infections: An analysis of 1117 hospitalized patients in Brazil. IJID Regions2025;16:100724.doi:10.1016/j.ijregi.2025.100724.

15.Popescu RI, Petca RC, Mares C, Petca A, Bassil M. Comparative Analysis of Antimicrobial Resistance in Male Uropathogens Before and After the COVID-19 Pandemic: A Single-Center Study from Romania.Medicina.2026;62(5):889.doi:10.3390/medicina62050889

16.Naidoo A, Kajee A, Mvelase NR, Swe-Han KS. Antimicrobial susceptibility of bacterial uropathogens in a South African regional hospital. African Journal of Laboratory Medicine. 2023;12(1):a1920. doi:10.4102/ajlm.v12i1.1920.

17.AlHemsi HB, Altamimi I, Altamimi A, Alhemsi HB, Alabdulkarim IM, Zawawi A, et al. Shifting Trends of Antimicrobial Resistance Patterns Among Uropathogenic Bacteria Before and During the COVID-19 Pandemic. Cereus.2024 Nov8;16(11):e73287.doi:10.7759/cureus.73287.

18.Alasmary MY. Antimicrobial Resistance Patterns and ESBL of Uropathogens Isolated from Adult Females in Najran Region of Saudi Arabia. Clinical Practice. 2021;11:650-658. doi:10.3390/clinpract11030080.

19.Mohapatra S, Venugopal SJ, Kalaivani M, Kant S, Tak V, Panigrahy R, et al. Antibiotic resistance of uropathogens among the community-dwelling pregnant and nonpregnant female: a step towards antibiotic stewardship.BMC Infectious Disease.2022;22:939.doi:10.1186/s12879-022-07914.

20.Kaushik C, Gangadhar NK, Bhat KS, Kotigadde S. Anti-biogram pattern of uro-pathogens isolated from patients in a Tertiary Care Hospital in Karnataka, India. *Indian Journal of Microbiology research*.2018;5(1):24-30.doi:10.18231/2394-5478.2018.0005.

21.Kalal BS, Nagaraj S. Urinary tract infections: a retrospective, descriptive study of causative organisms and antimicrobial pattern of samples received for culture, from a tertiary care setting. GERMS.2016;6(4):132-138.doi.10.11599/germs.2016.1100

22.Tariq TM. Frequency of uropathogens showing resistance to Nitrofurantoin. *Journal of Pakistan*

Medical Association.2023;73(7):1495-1497.doi:10.47391/JPMA.7616

23.Oli AN, Akabueze VB, Ezeudu CE, Eleje GU, Ejiofor OS, Ezebialu IU, et al. Bacteriology and Antibiogram of Urinary Tract Infection Among Female Patients in a Tertiary Health Facility in South Eastern Nigeria.*Open Microbiology Journal*.2017;11:292-300.doi:10.2174/1874285801711010292.

24.Bitew G, Dagnew M, Dereje M, Birhanu A, Yalewayker Gashaw, Ambachew A, et al. Burden of multi-drug resistant bacterial isolates and its associated risk factors among UTI-confirmed geriatrics in Gondar town.Scientific Reports.2025;15(1):14270.doi:10.1038/s 41598-025-89123-9.

25.Chikkannasetty Somashekara S, Deepalaxmi S, Jagannath N, Ramesh B, Ravindran Laveesh M, Govindadas D. Retrospective analysis of antibiotic resistance pattern to urinary pathogens in a Tertiary Care Hospital in South India. *Journal of Basic and Clinical Pharmacology*. 2011 Nov;2(4):19-24. doi:10.47391/ijbcp20111126.

26.Vijay Prakash Singh, Abhishek Mehta. Bacteriological profile of urinary tract infections at a tertiary care hospital in Western Uttar Pradesh, India. *International Journal of Research in Medical Sciences*.2017;5(5):2126-2129.doi:10.18203/2320-6012.ijrms20171855.

27.Gagan Chooramani, Bhawana Jain, Prashant Singh Chauhan. Prevalence and antimicrobial sensitivity pattern of bacteria causing urinary tract infection; study of a tertiary care hospital in North India. Clinical Epidemiology and Global Health.2020;8(3):890-893.doi:10.1016/j.cegh.2020.02.018.

28. Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.*Journal of Clinical Infectious Disease*. 2018;67(6):e1-e94

29. Wilson MR, O'Donovan BD, Gelfand JM, et al. Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing. JAMA Neurol. 2018;75(4):494-500.

30. Timbrook TT, Morton JB, McConeghy KW, et al. The Effect of Rapid Molecular Diagnostic Testing on Clinical Outcomes of Bloodstream Infections: A Systematic Review and Meta-analysis. Clinical Infectious Disease. 2017;64(1):15-23.

31.Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Disease. 2016;62(10):e51-e77.

32.Morgan DJ, Malani P, Diekema DJ. Diagnostic Stewardship—Leveraging the Laboratory to Improve Antimicrobial Use. JAMA. 2017;318(7):607-608.

33.World Health Organization.Antimicrobial resistance[Internet].Geneva:World Health Organization;2024[cited 2026 Jun 13].Available from:https://www.who.int/news-room/factsheets/detail/antimicrobial-resistance.

34.European Centre for Disease Prevention and Control.Factsheet for the general public Antimicrobial resistance[Internet].Stockholm:ECDC;2024[cited 2026 Jun 13].Available from https://www.ecdc.europa.eu/en/antimicrobial-resistance/facts/factsheet/general public.

35.Sawant AJ,Thete SR,Kadam KV.Comprehensive review on antimicrobial resistance:mechanisms,drivers,impacts and strategies for mitigation.Innovative journal of Innovative research in Technology.2025 May;11(12):6250-6258.

36.StatPearls[Internet].Treasure Island(FL):StatPearls Publishing:2025 Jan.Antibiotic resistance;[updated 2025;cited 2026 Jun 13].Available from , https://www.ncbi.nlm.nih.gov/books/NBK513277/

37.Muhammed A.Review on antimicrobial resistance:mechanism of spread and novel approaches to diagnostics.Open Access Journal of Diseases and Global Health.2025;3(1):1-8

38. Barlam TF Cosgrove SE, Jenkins MN, Christian LM, Kalil AC, Newland JG, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases. 2016 May;62(10):e51-e77. doi:10.1093/cid/ciw118.

39. CDC. Core Elements of Hospital Antibiotic Stewardship Programs [Internet]. Atlanta (GA): US Department of Health and Human Services, CDC; 2019 [updated 2023; cited 2026 Jun 13]. Available from: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html

40. Sawant AJ, Thete SR, Kadam KV. Comprehensive review on antimicrobial resistance: mechanisms, drivers, impacts, and strategies for mitigation.Innovative Journal of Innovative Research in Technology. 2025 May;11(12):6250-6258.

41. Public Health Ontario. Antimicrobial Stewardship Strategy: Antibiograms [Internet]. Toronto: Queen's Printer for Ontario; 2016 [updated 2021; cited 2026 Jun 13]. Available from: https://www.publichealthontario.ca/-/media/Documents/A/2016/asp-antibiograms.pdf

42.Antinori S, Pezzani MD. Uncomplicated and complicated urinary tract infections in adults: The infectious diseases's specialist perspective. In: Tonolini M, editor. Imaging and Intervention in Urinary Tract Infections and Urosepsis. Cham: Springer International Publishing; 2017. p. 17–33.

43.Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nature Review Microbiology*. 2015;13(5):269–284.

44.Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: The current scenario and future prospects. Pathogens. 2023;12(4):62